Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia
Status:
Completed
Trial end date:
2020-12-22
Target enrollment:
Participant gender:
Summary
This was a multicenter, randomized, double-blind, placebo-controlled study to assess the
efficacy and safety of canakinumab plus standard-of-care (SOC) compared with placebo plus SOC
in patients with COVID-19-induced pneumonia and cytokine release syndrome (CRS).